These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 32476108)

  • 1. NUC-1031 in biliary tract cancer: from bench to bedside and back?
    Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
    Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
    Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
    Arora M; Bogenberger JM; Abdelrahman A; Leiting JL; Chen X; Egan JB; Kasimsetty A; Lenkiewicz E; Malasi S; Uson PLS; Nagalo BM; Zhou Y; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Truty MJ; Borad MJ
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1063-1078. PubMed ID: 32440762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
    Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
    Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".
    Ricci AD; Rizzo A; Brandi G
    Oncologist; 2021 May; 26(5):e902. PubMed ID: 33539601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for the biliary tract cancers: moving toward improved survival time.
    Romiti A; D'Antonio C; Zullo A; Sarcina I; Di Rocco R; Barucca V; Durante V; Marchetti P
    J Gastrointest Cancer; 2012 Sep; 43(3):396-404. PubMed ID: 22328060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
    Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
    Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and histological stratification of biliary tract cancers.
    Cariati A; Piromalli E
    Oncology; 2012; 82(6):352-3. PubMed ID: 22677952
    [No Abstract]   [Full Text] [Related]  

  • 10. Biliary tract cancer stem cells - translational options and challenges.
    Mayr C; Ocker M; Ritter M; Pichler M; Neureiter D; Kiesslich T
    World J Gastroenterol; 2017 Apr; 23(14):2470-2482. PubMed ID: 28465631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward personalized treatment of advanced biliary tract cancers.
    Geynisman DM; Catenacci DV
    Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells
    Slusarczyk M; Serpi M; Ghazaly E; Kariuki BM; McGuigan C; Pepper C
    J Med Chem; 2021 Jun; 64(12):8179-8193. PubMed ID: 34085825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging molecular target antagonists for the treatment of biliary tract cancer.
    Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimum chemotherapy for the management of advanced biliary tract cancer.
    Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
    World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine.
    Patel D; Dickson AL; Zickuhr GM; Um IH; Read OJ; Czekster CM; Mullen P; Harrison DJ; Bré J
    Transl Oncol; 2024 Dec; 50():102114. PubMed ID: 39299019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surgical outcome of biliary tract cancer with neoadjuvant chemotherapy].
    Kato A; Shimizu H; Yoshidome H; Otsuka M; Furukawa K; Yoshitomi H; Takeuchi D; Takayashiki T; Kuboki S; Suzuki D; Nakajima M; Miyazaki M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1486-9. PubMed ID: 23133873
    [No Abstract]   [Full Text] [Related]  

  • 18. [Surgical outcome of biliary tract cancer with postoperative chemotherapy].
    Sugawara G; Ebata T; Yokoyama Y; Igami T; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1483-5. PubMed ID: 23130375
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
    Boku N
    Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.